135 related articles for article (PubMed ID: 25586350)
21. Vascular endothelial growth factor (VEGF) expression in prostate cancer and benign prostatic hyperplasia.
Jackson MW; Bentel JM; Tilley WD
J Urol; 1997 Jun; 157(6):2323-8. PubMed ID: 9146664
[TBL] [Abstract][Full Text] [Related]
22. Human telomerase reverse transcriptase expression correlates with vascular endothelial growth factor-promoted tumor cell proliferation in prostate cancer.
Tang J; Wang Z; Li X; Li J; Shi H
Artif Cells Blood Substit Immobil Biotechnol; 2008; 36(2):83-93. PubMed ID: 18437586
[TBL] [Abstract][Full Text] [Related]
23. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
24. Adiponectin mediates antiproliferative and apoptotic responses in endometrial carcinoma by the AdipoRs/AMPK pathway.
Zhang L; Wen K; Han X; Liu R; Qu Q
Gynecol Oncol; 2015 May; 137(2):311-20. PubMed ID: 25703675
[TBL] [Abstract][Full Text] [Related]
25. [Expression of cyclooxygenase-2 and vascular endothelial growth factor in human prostate cancer and its significance].
Jin TX; Li XG; Wu WY; Piao DM; Feng JY; Sang J
Zhonghua Nan Ke Xue; 2006 Mar; 12(3):207-10. PubMed ID: 16597032
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer and adiponectin.
Goktas S; Yilmaz MI; Caglar K; Sonmez A; Kilic S; Bedir S
Urology; 2005 Jun; 65(6):1168-72. PubMed ID: 15922427
[TBL] [Abstract][Full Text] [Related]
27. Secretion of soluble VEGF receptor 2 by microvascular endothelial cells derived by human benign prostatic hyperplasia.
Stachon A; Aweimer A; Stachon T; Tannapfel A; Thoms S; Ubrig B; Köller M; Krieg M; Truss MC
Growth Factors; 2009 Apr; 27(2):71-8. PubMed ID: 19199116
[TBL] [Abstract][Full Text] [Related]
28. The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase.
Zakikhani M; Dowling RJ; Sonenberg N; Pollak MN
Cancer Prev Res (Phila); 2008 Oct; 1(5):369-75. PubMed ID: 19138981
[TBL] [Abstract][Full Text] [Related]
29. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease.
Kaushal V; Mukunyadzi P; Dennis RA; Siegel ER; Johnson DE; Kohli M
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):584-93. PubMed ID: 15701844
[TBL] [Abstract][Full Text] [Related]
30. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer.
Stefanou D; Batistatou A; Kamina S; Arkoumani E; Papachristou DJ; Agnantis NJ
In Vivo; 2004; 18(2):155-60. PubMed ID: 15113042
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity.
Kitagawa Y; Dai J; Zhang J; Keller JM; Nor J; Yao Z; Keller ET
Cancer Res; 2005 Dec; 65(23):10921-9. PubMed ID: 16322239
[TBL] [Abstract][Full Text] [Related]
32. GABARBP down-regulates HIF-1α expression through the VEGFR-2 and PI3K/mTOR/4E-BP1 pathways.
Park SH; Kim BR; Lee JH; Park ST; Lee SH; Dong SM; Rho SB
Cell Signal; 2014 Jul; 26(7):1506-13. PubMed ID: 24686084
[TBL] [Abstract][Full Text] [Related]
33. Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia.
Soulitzis N; Karyotis I; Delakas D; Spandidos DA
Int J Oncol; 2006 Aug; 29(2):305-14. PubMed ID: 16820871
[TBL] [Abstract][Full Text] [Related]
34. The relationship between proangiogenic gene expression levels in prostate cancer and their prognostic value for clinical outcomes.
Mori R; Dorff TB; Xiong S; Tarabolous CJ; Ye W; Groshen S; Danenberg KD; Danenberg PV; Pinski JK
Prostate; 2010 Nov; 70(15):1692-700. PubMed ID: 20564320
[TBL] [Abstract][Full Text] [Related]
35. Increased expression of VEGF121/VEGF165-189 ratio results in a significant enhancement of human prostate tumor angiogenesis.
Catena R; Muniz-Medina V; Moralejo B; Javierre B; Best CJ; Emmert-Buck MR; Green JE; Baker CC; Calvo A
Int J Cancer; 2007 May; 120(10):2096-109. PubMed ID: 17278099
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells.
Inoue S; Branch CD; Gallick GE; Chada S; Ramesh R
Mol Ther; 2005 Oct; 12(4):707-15. PubMed ID: 16054437
[TBL] [Abstract][Full Text] [Related]
37. Suppression of VEGF expression through interruption of the HIF‑1α and Akt signaling cascade modulates the anti‑angiogenic activity of DAPK in ovarian carcinoma cells.
Park ST; Kim BR; Park SH; Lee JH; Lee EJ; Lee SH; Rho SB
Oncol Rep; 2014 Feb; 31(2):1021-9. PubMed ID: 24337450
[TBL] [Abstract][Full Text] [Related]
38. Adiponectin-induced antitumor activity on prostatic cancers through inhibiting proliferation.
Gao Q; Zheng J
Cell Biochem Biophys; 2014 Sep; 70(1):461-5. PubMed ID: 24793551
[TBL] [Abstract][Full Text] [Related]
39. Adiponectin inhibits PDGF-induced mesangial cell proliferation: regulation of mammalian target of rapamycin-mediated survival pathway by adenosine 5-monophosphate-activated protein kinase.
Su YX; Deng HC; Zhang MX; Long J; Peng ZG
Horm Metab Res; 2012 Jan; 44(1):21-7. PubMed ID: 22105511
[TBL] [Abstract][Full Text] [Related]
40. Reexpression of ARHI inhibits tumor growth and angiogenesis and impairs the mTOR/VEGF pathway in hepatocellular carcinoma.
Zhao X; Li J; Zhuo J; Cai L
Biochem Biophys Res Commun; 2010 Dec; 403(3-4):417-21. PubMed ID: 21093415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
